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In an era of spiraling health care costs and limited resources, policy makers and health care payers are concerned about the
cost eﬀectiveness of antibiotics. The aim of this study is to draw on published economic evaluations with a view to identify and
illustrate the factors aﬀecting the cost eﬀectiveness of antibiotic treatment of bacterial infections. The ﬁndings indicate that the
cost eﬀectiveness of antibiotics is inﬂuenced by factors relating to the characteristics and the use of antibiotics (i.e., diagnosis,
comparative costs and comparative eﬀectiveness, resistance, patient compliance with treatment, and treatment failure) and by
external factors (i.e., funding source, clinical pharmacy interventions, and guideline implementation interventions). Physicians
need to take into account these factors when prescribing an antibiotic and assess whether a speciﬁc antibiotic treatment adds
suﬃcient value to justify its costs.
1.Introduction
Antibiotics have made a signiﬁcant contribution to improv-
ing the health of patients suﬀering from bacterial infections.
For instance, antibiotics are commonly used in the treatment
of lower respiratory tract infections. The scientiﬁc literature
and international guidelines recommend antibiotic therapy
in patients with acute exacerbations of chronic obstruc-
tive pulmonary disease (COPD) and community-acquired
pneumonia (CAP) [1–3]. Also, antibiotics appear eﬀective
in improving cure rates and decreasing duration of acute
sinusitis in patients who have a microbiological diagnosis
of bacterial infection or severe disease [4]. In fact, the
added value of antibiotics for therapeutic and prophylactic
purposes is so persuasive that many older antibiotics never
underwent controlled clinical trials [5].
In an era of spiraling health care costs and limited
resources, policy makers and health care payers are also con-
cerned about the cost eﬀectiveness of antibiotics. Economic
evaluationisatechniquethatassessesthecosteﬀectivenessof
antibiotics by exploring whether antibiotic treatment makes
as u ﬃcient contribution to health to justify its costs. An
economic evaluation is deﬁned as a comparative analysis of
at least two health technologies in terms of both their costs
and outcomes [6].
Information about the cost eﬀectiveness of antibiotic
treatment of bacterial infections can be used for decision-
making purposes by a variety of stakeholders [7]. Policy
makerscanuseeconomicevaluationtoinformtheallocation
of scarce health care resources. Health care payers in
an increasing number of countries apply evidence about
cost eﬀectiveness to inform drug pricing/reimbursement
decisions (see Table 1). Antibiotics that provide better cost
eﬀectiveness are rewarded by means of a more favourable
price/reimbursement. Health care professionals can rely on
economic evaluation to shed light on alternative approaches
to treat bacterial infections. Finally, pharmaceutical com-
panies can employ techniques of economic evaluation to
demonstrate the cost eﬀectiveness of their antibiotics.
A number of economic evaluations assessing the cost
eﬀectiveness of antibiotic treatment of bacterial infections
have been published in the literature. The aim of this study
is to identify and discuss the factors that aﬀect the cost
eﬀectiveness of antibiotics.
2.MaterialsandMethods
The literature review did not focus on presenting evidence
about the cost eﬀectiveness of antibiotics but rather drew
on published economic evaluations with a view to identify2 Chemotherapy Research and Practice
Table 1: Use of economic evaluation in drug pricing/reimbursement.
Country Organisation Implementation date
Australia Pharmaceutical Beneﬁts Advisory Committee 1993
Belgium Medicine Reimbursement Committee 2002
England and Wales National Institute for Health and Clinical Excellence 1999
France High Health Authority 2008
Germany Institute for Quality and Eﬃciency in Health Care 2007
Netherlands Health Care Insurance Board 1999
New Zealand Pharmaceutical Management Agency 1993
Scotland Scottish Medicines Consortium 2002
Sweden Dental and Pharmaceutical Beneﬁts Agency 2002
Taiwan Centre for Drug Evaluation 2008
and illustrate the factors aﬀecting the cost eﬀectiveness of
antibiotic treatment of bacterial infections. As such, the
literaturereviewofeconomicevaluationswasnotsystematic.
Economic evaluations were identiﬁed by searching
PubMed, Centre for Reviews and Dissemination databases
(Database of Abstracts of Reviews of Eﬀects, National
Health Service Economic Evaluation Database, and Health
Technology Assessments Database), Cochrane Database of
Systematic Reviews, and EconLit up to September 2010.
Additionally, the bibliography of included studies was
checked for other relevant studies. Search terms related to
multiple infection types and antibiotic classes and included
“pharmaco-economics,” “economic evaluation,” “cost eﬀec-
tiveness,” “cost minimisation,” “cost utility,” and “cost bene-
ﬁt” alone and in combination with each other.
The review focused on studies published between 1995
and 2010. Earlier studies were considered to be of limited
practical relevance due to likely changes over time in
antibiotic treatment modalities and in the organisation and
ﬁnancing of health care systems. Both original economic
evaluations and literature reviews of economic evaluations
were included.
3. Results
The cost eﬀectiveness of antibiotic treatment of bacterial
infections is inﬂuenced by factors relating to the character-
istics and the use of antibiotics (i.e., diagnosis, compara-
tive costs and comparative eﬀectiveness, resistance, patient
compliance with treatment, and treatment failure) and by
external factors (i.e., funding source, clinical pharmacy
interventions, and guideline implementation interventions)
(see Figure 1).
3.1. Diagnosis. Diagnosing a bacterial infection is rendered
diﬃcult by the fact that the diagnosis is generally based on
patients’ self-reported clinical symptoms. This is exempliﬁed
with the case of COPD exacerbations. The diagnosis of
a COPD exacerbation is complex because exacerbations
are heterogeneous and there is debate about the deﬁnition
of an exacerbation. Furthermore, in practice, high-quality
sputum specimens are not always available [8]. This implies
that exacerbations are not always identiﬁed as such and
appropriate treatment is not always administered. In fact,
there is evidence that up to 50% of exacerbations are
not identiﬁed by a health care professional when using a
symptom-based deﬁnition [9].
With respect to the identiﬁcation of the bacterial aeti-
ology, a Spanish economic evaluation showed that the
most valuable treatment strategy for CAP depended on the
bacterial pathogen involved and the physician needed to
adapt the antibiotic treatment strategy to the cause [10].
The authors concluded that amoxicillin 1g for treating CAP
was more eﬀective and less expensive than moxiﬂoxacin,
telithromycin, or clarithromycin if the physician was able to
discriminate clinically the bacterialaetiology. If the physician
needed to initiate empirical treatment in the absence of
information about the causative pathogen and the antibiotic
susceptibility pattern of the isolated organism, moxiﬂoxacin
became the most valuable option. However, the model of
treatment pathways in this study was necessarily simplistic,
and future modelling work in this domain would beneﬁt
from better and more recent data on resistance.
Viruses can be mistaken for microbial pathogens and
maybetreatedempiricallywithantibiotics.Forinstance,two
economic evaluations using the same study design explored
the cost eﬀectiveness of moxiﬂoxacin in the treatment
of CAP in diﬀerent countries [11, 12]. Viruses were not
considered in the base case analysis, and results indicated
that moxiﬂoxacin was more eﬀective and less expensive
than alternative antibiotics. A sensitivity analysis considered
viruses with respect to the prevalence of pathogens; the
study assumed a normalized frequency distribution of 20%
for viruses, 54% for S. pneumoniae,8 %f o rH. inﬂuenza,
and 18% for atypical pathogens. Antibiotic treatment of
pathogens including viruses reduced health care costs, the
rate of ﬁrst-line clinical failure, and the hospitalization rate
but did not change the overall conclusions about the cost
eﬀectiveness of moxiﬂoxacin. As these economic evaluations
were carried out from the perspective of the third-party
payer, the analyses considered health care costs only and did
not include costs due to productivity loss. The inclusion of
indirect costs would result in an even better cost eﬀectiveness















Figure 1: Factors aﬀecting the cost eﬀectiveness of antibiotics.
3.2. Comparative Costs and Comparative Eﬀectiveness. The
comparative costs and comparative eﬀectiveness of antibi-
otics play a key role in determining the cost eﬀectiveness of
antibiotic treatment of bacterial infections.
As t u d yc a r r i e do u ta ne c o n o m i ce v a l u a t i o no ft h eu s e
of teicoplanin and vancomycin in the treatment of intensive
care unit patients with catheter-related infections [13].
Comparative trials of teicoplanin and vancomycin reported
nosigniﬁcantdiﬀerencesintheireﬃcacy[14,15]and,hence,
the authors conducted a cost minimisation analysis. In a
cost minimisation analysis, only costs are analysed and the
least costly treatment approach is chosen because outcomes
are known to be equal between approaches. This study
elicited data about resource use based on a Delphi panel
of nine experts rather than actually observing resource use
in patients. Mean treatment costs per patient amounted to
1,272 C with teicoplanin and 1,041 C with vancomycin. The
higher treatment cost with teicoplanin mainly originated
from higher drug acquisition costs. Treatment costs of
teicoplanin and vancomycin turned out to be sensitive to
changes in drug unit costs and unit costs of serum level
monitoring tests.
AliteraturereviewofantibiotictreatmentofCOPDexac-
erbations focused on the comparative costs and the compar-
ativeeﬀectivenessofﬁrst-generationantibiotics(aminopeni-
cillins, macrolides, and tetracyclines) and second-generation
antibiotics (e.g., ﬂuoroquinolones) [16]. Fluoroquinolones
generally had higher acquisition costs than ﬁrst-generation
antibiotics. Traditionally, studies suggested that second-
generation macrolides and ﬂuoroquinolones are equally
eﬀective as ﬁrst-generation antibiotics [17]. If this is the
case, the cost eﬀectiveness of antibiotic treatment can be
determined by means of a cost minimisation analysis.
However, this literature was limited by the fact that most
trials were powered to demonstrate equivalence rather than
clinical superiority, had enrolled small samples that are not
always representative of the patient population, and did
not control for concomitant therapy or for comorbidities.
Also, more recent evidence suggested that management of
COPD exacerbations with moxiﬂoxacin or gemiﬂoxacin is
associated with a shorter time to resolution of symptoms,
a lower hospitalisation rate, and a prolonged exacerbation-
free interval, thereby generating clinical beneﬁts as well as
cost savings [18, 19]. In general, there is a need for economic
evaluations to determine the cost eﬀectiveness of treating
COPD exacerbations by comparing the comparative costs of
antibiotics with their comparative eﬀectiveness.
3.3. Resistance. When antibiotics ﬁrst became available,
changes in the susceptibility of pathogens were of little
concern. However, inappropriate use of antibiotics, (human-
to-human) clonal spread of multidrug-resistant strains, and
the presence of comorbidities have all contributed to the
rise in resistance over the years. Resistance to antibiotics
can have a substantial impact on outcomes and costs of
treatment. For instance, there is evidence that CAP patients
with pneumococcal resistance may be at greater risk of
poor outcomes [20]. Also, if ﬁrst-line treatment fails due to
resistance, additional costs are incurred due to the need for
second-line treatment or hospitalization, or both.
Using evidence from four economic evaluations of
antibiotic treatment of mild-to-moderate CAP in Belgium,
Canada, France, Spain, and the United States [10–12, 21], it
is possible to examine the impact of resistance on the cost
eﬀectiveness of antibiotics. The studies employed a similar
study design; decision-analytic models evaluated the cost
eﬀectiveness of oral antibiotics from the third-party payer
perspective, with ﬁrst-line treatment being initiated in the
community and failure resulting in second-line treatment in
thecommunityorhospitalization.Theﬁrst-lineintervention
wasmoxiﬂoxacinineachstudy.Comparatortreatmentswere
beta-lactams (e.g., coamoxiclav, cefuroxime), macrolides
(e.g., clarithromycin, azithromycin), or tetracyclines (e.g.,
doxycycline).Eﬀectivenesswasassessedintermsoftherateof
ﬁrst-line clinical failures, of second-line treatments required,
of hospitalizations required, and of mortality.
The impact of resistance on the cost eﬀectiveness of
antibiotics was investigated in two ways. First, sensitivity
analyses examined the impact of various resistance rates for
S. pneumoniae and H. inﬂuenzae on the cost eﬀectiveness
of antibiotics. Second, results on cost eﬀectiveness can be
compared between economic evaluations and thus between
countries with diﬀerent levels of resistance; Germany has
a low level of resistance in CAP pathogens [22]; Belgium,
Canada, and the United States have an intermediate level
of resistance [23–25]; France and Spain have a high level of
resistance[22].However,itshouldbenotedthatfactorsother
than resistance may explain diﬀerences in results between4 Chemotherapy Research and Practice
these economic evaluations (e.g., costs of care, treatment
protocols).
The sensitivity analyses and the comparison between
countries indicated that varying levels of resistance in CAP
pathogensandmultidrugresistanceinS.pneumoniaeisolates
aﬀected costs and clinical outcomes of antibiotic treatment
[10–12]. However, conclusions did not change; treatment of
CAP with moxiﬂoxacin was more eﬀective and less expensive
thanotherantibiotictreatmentstrategiesinBelgium,France,
Germany, Spain, and the United States. At the moment,
worldwide resistance of CAP pathogens to moxiﬂoxacin is
low[26]butcontinuedvigilancewithregardtotheevolution
of resistance and its impact on the cost eﬀectiveness of
moxiﬂoxacin and of other antibiotics is indicated.
In Canada, the sensitivity analysis showed that a 50%
increase in ﬂuoroquinolone resistance would decrease the
cost eﬀectiveness of moxiﬂoxacin treatment as compared
with azithromycin to CAN$ 101.47 per ﬁrst-line clinical
failure avoided [21]. Canada has faced a steady increase in
macrolide resistance in S. pneumoniae over time [23], and
further increases in macrolide resistance rates cannot be
ruled out. Increases in macrolide resistance would improve
the cost eﬀectiveness of treatment with moxiﬂoxacin.
3.4. Patient Compliance. The cost eﬀectiveness of antibiotic
treatment also depends on patient compliance, with com-
pliance being aﬀected by the frequency of dosing, duration
of treatment, adverse events, ease of administering drugs,
ease of packaging, and price [27]. An economic evaluation
of antibiotic treatment quantiﬁed patient compliance; rates
of compliance deﬁned as an intake of at least 80% of the
prescribed dose varied between 76% and 83% [28]. Various
strategies to enhance patient compliance with antibiotic
treatment have been proposed such as patient education,
once-daily dosing schedules, a convenient and acceptable
form of medication, easy-to-open packaging, and the choice
of an antibiotic with few side eﬀects [27].
3.5. Treatment Failure. Resistance to antibiotics and patient
compliancemayinﬂuencethecosteﬀectivenessofantibiotics
becausetheymayleadtotreatmentfailureandfurtherantibi-
otic treatment or hospitalisation. For instance, a literature
review of the distribution of health care costs of COPD
exacerbations found that hospitalization costs accounted for
more than 45% of health care costs and drugs costs made
up between 6% and 21% of costs [16]. As hospitalization
is generally indicative of treatment failure, these estimates
highlight the cost eﬀectiveness that can be attained from
more eﬀective antibiotics that allow patients to be managed
in primary care and that prevent treatment failure and
hospitalization. In other words, if a new antibiotic would
have a lower failure rate than alternative treatments, it would
be likely to be cost eﬀective, even if it is more expensive than
other antibiotics.
Treatment failure may be caused by a number of host
factors. The literature suggests that frequency of exacerba-
tions, presence of comorbidities, impairment in lung func-
tion, need for more aggressive bronchodilator therapy, and
previous hospitalization predict treatment failure [29, 30].
The ability to identify patients at a higher risk of failing
treatment can aid clinicians in their choice of antibiotic. This
implies that it may be advisable to identify patient subgroups
inwhichtreatmentwithaspeciﬁcantibioticprovidesthebest
costeﬀectivenessandshouldberecommended byguidelines.
3.6. Funding Source. A recent study extracted the cost eﬀec-
tiveness of antibiotics from economic evaluations included
in the Tufts-New England Center Cost Eﬀectiveness Analysis
RegistrythroughSeptember2009[31].Theanalysisincluded
85 observations on the cost eﬀectiveness of antibiotics
derived from 23 economic evaluations. Economic eval-
uations related to infectious diseases (58% of studies),
respiratory diseases (13%), cardiovascular diseases (9%),
critical care (4%), endocrine disorders (4%), genitor-urinary
diseases (4%), musculoskeletal and rheumatologic diseases
(4%), and sensory organ diseases (4%). The results indicated
thatthemedianincrementalcosteﬀectivenessratioofantibi-
otics was 748 C per quality-adjusted life year. Speciﬁcally,
38.8% of antibiotics were more eﬀective and less costly than
the comparator; 45.9% of antibiotics improved eﬀectiveness
but also increased costs; 15.3% of antibiotics were less
eﬀective and more costly than the comparator.
Thecosteﬀectivenessofantibioticsderivedfromanalyses
fundedbyindustrytendedtobebetterthanthecosteﬀective-
ness derived from analyses funded from other sources (e.g.,
government, foundations). However, the limited number of
observations implied that it was not possible to statistically
testforthisassociation.Also,thereweretoofewobservations
to explore whether there was an association between the
methodological quality of economic evaluations and the
funding source. The possible association between cost eﬀec-
tiveness and funding source may have several explanations;
industry inﬂuences the design of economic evaluations with
a view to improving the cost eﬀectiveness of their products;
as costs of research and development are high, industry
marketsthoseantibioticsthatarecosteﬀectiveonly;industry
sponsors economic evaluations of antibiotics that are likely
to be cost eﬀective only; researchers conduct and journal
editors publish those economic evaluations that support the
cost eﬀectiveness of antibiotics. In response to the possible
manipulation of studies, professional societies and health
carepayersareincreasinglyissuingguidelinesfortheconduct
and reporting of economic evaluations.
3.7. Clinical Pharmacy. During the last decades, clinical
pharmacy services have developed around the world [32].
Even if there exists no consensus concerning the term
“clinical pharmacy,” clinical pharmacy can be deﬁned as
the contribution of pharmacists and their assistants to drug
therapy as a part of the total care supplied to patients, in
cooperation with physicians and nursing staﬀ,w i t hav i e w
to optimizing the cost eﬀectiveness, the eﬀectiveness, and the
safety of drug therapy.
A literature review examined the cost eﬀectiveness of
clinical pharmacy interventions focusing on the manage-
ment of antibiotic therapy in a hospital setting [33]. Extract-
ing evidence from six economic evaluations, the authors
concluded that clinical pharmacy interventions relating toChemotherapy Research and Practice 5
antibiotic therapy can lower costs of hospital care without
adversely aﬀecting clinical outcomes. Lower costs arose from
a decrease in drug costs (e.g., due to switch from intravenous
tooraldrugs),lowerpharmacycosts,andadecreaseinlength
of stay. However, economic evaluations of clinical pharmacy
interventions suﬀered from a number of methodological
limitations relating to the absence of a control group without
clinical pharmacy interventions; limited scope of costs and
outcomes; focus on direct healthcare costs only; exclusion of
pharmacist employment cost; use of intermediate outcome
measures; exclusion of health beneﬁts; absence of incremen-
tal analysis.
3.8. Guideline Implementation. Numerous guidelines have
been published governing appropriate antibiotic treatment
of bacterial infections. Interventions surrounding the imple-
mentation of guidelines may have an impact on health care
professional compliance with guidelines and, hence, may
inﬂuence the cost eﬀectiveness of antibiotics.
A literature review evaluated the cost eﬀectiveness of
antibiotic treatment consistent with guidelines for patients
with CAP [34]. This literature indicated that antibiotic
treatment consistent with guidelines reduced length of stay,
decreased costs, and reduced the mortality rate. How-
ever, existing studies suﬀered from methodological limita-
tions, and high-quality economic evaluations examining the
impact of guideline implementation interventions on the
cost eﬀectiveness of antibiotic treatment are needed.
4. Conclusions
This study has identiﬁed and discussed the factors that aﬀect
thecosteﬀectivenessofantibiotics.Theﬁndingsindicatethat
the cost eﬀectiveness of antibiotics is inﬂuenced by factors
relating to the characteristics and the use of antibiotics (i.e.,
diagnosis, comparative costs and comparative eﬀectiveness,
resistance,patientcompliancewithtreatment,andtreatment
failure) and by external factors (i.e., funding source, clini-
cal pharmacy interventions, and guideline implementation
interventions). Physicians need to take into account these
factors when prescribing an antibiotic and assess whether a
speciﬁc antibiotic treatment adds suﬃcient value to justify
its costs. Finally, it should be noted that cost eﬀectiveness
is only one of the factors and not necessarily the most
important factor informing the choice of physicians between
antibiotics. Other factors that need to be taken into account
include,forexample,routeofadministration,patientproﬁle,
and the occurrence of adverse events.
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